Download PDF
Frauenheilkunde up2date 2015; 9(05): 325-333
DOI: 10.1055/s-0033-1358189
Allgemeine Gynäkologie und gynäkologische Onkologie
Georg Thieme Verlag KG Stuttgart · New York

Seltene Tumoren: mesenchymale Tumoren des Uterus

Philipp Harter
,
Beyhan Ataseven
,
Florian Heitz
,
Andreas du Bois
Further Information

Publication History

Publication Date:
27 October 2015 (online)

Also available at
    Permissions and Reprints All articles of this category
Kernaussagen

Uterussarkome sind seltene, aggressive mesenchymale Tumoren mit relativ schlechter Prognose. Sie umfassen diverse histologische Subtypen, etwa Leiomyosarkome, Low- und High-Grade endometriale Stromasarkome, undifferenzierte uterine Sarkome und viele andere, die entsprechend unterschiedliche operative und system- bzw. strahlentherapeutische Strategien erfordern. Die gegenwärtig verfügbare Evidenz zur operativen, adjuvanten und palliativen Therapie wird dargestellt.

 

  • Literatur

  • 1 DʼAngelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116: 131-139
    CrossrefGoogle Scholar
  • 2 Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986; 76: 399-402
    Google Scholar
  • 3 Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005; 366: 491-505
    CrossrefGoogle Scholar
  • 4 Gadducci A, Cosio S, Romanini A et al. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 2008; 65: 129-142
    CrossrefGoogle Scholar
  • 5 Graebe K, Garcia-Soto A, Aziz M et al. Incidental power morcellation of malignancy: a retrospective cohort study. Gynecol Oncol 2015; 136: 274-277
    CrossrefGoogle Scholar
  • 6 Park JY, Park SK, Kim DY et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 2011; 122: 255-259
    CrossrefGoogle Scholar
  • 7 Beckmann MW, Juhasz-Böss I, Denschlag D et al. Surgical methods for the treatment of uterine fibroids – risk of uterine sarcoma and problems of morcellation: position paper of the DGGG. Geburtshilfe Frauenheilkd 2015; 75: 148-164
    Article in Thieme ConnectGoogle Scholar
  • 8 Mowers EL, Skinner B, McLean K et al. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommen-dations for clinical practice. J Minim Invasive Gynecol 2015; 22: 601-606
    CrossrefGoogle Scholar
  • 9 Reed NS, Mangioni C, Malmstrom H et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818
    CrossrefGoogle Scholar
  • 10 Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 573-581
    CrossrefPubMedGoogle Scholar
  • 11 Pautier P, Floquet A, Gladieff L et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol 2013; 24: 1099-1104
    CrossrefGoogle Scholar
  • 12 Hensley ML, Wathen JK, Maki RG et al. Adjuvant therapy for high-grade, uterus-limited leiomyo-sarcoma: results of a phase 2 trial (SARC005). Cancer 2013; 119: 1555-1561
    CrossrefGoogle Scholar
  • 13 Leitao jr. MM, Zivanovic O, Chi DS et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol 2012; 125: 409-413
    CrossrefGoogle Scholar
  • 14 Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25: 2755-2763
    CrossrefPubMedGoogle Scholar
  • 15 Hensley ML, Miller A, OʼMalley DM et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2015; 33: 1180-1185
    CrossrefGoogle Scholar
  • 16 Seddon BM, Whelan J, Strauss SJ et al. GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009–014907-29). J Clin Oncol 2015; 33 (suppl) abstr 10500
    Google Scholar
  • 17 Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196
    CrossrefPubMedGoogle Scholar
  • 18 van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PAL-ETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886
    CrossrefPubMedGoogle Scholar
  • 19 Demetri GD, Chawla SP, Ray-Coquard I et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013; 31: 2485-2492
    CrossrefPubMedGoogle Scholar
  • 20 Schöffski P, Maki RG, Italiano A et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 2015; 33 (suppl) abstr LBA10502
    Google Scholar
  • 21 Harter P, Canzler U, Lueck H et al. Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: a phase II trial of the AGO study group. J Clin Oncol, ASCO Annual Meeting Abstracts 2011; 29 (Suppl. 15) Abstract 5093
    Google Scholar
  • 22 Garcia-Del-Muro X, Lopez-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29: 2528-2533
    CrossrefGoogle Scholar
  • 23 Pautier P, Floquet A, Cupissol D et al. LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS. J Clin Oncol 2013; 31 (suppl) abstr 10505
    CrossrefGoogle Scholar
  • 24 Jin Y, Pan L, Wang X et al. Clinical characteristics of endometrial stromal sarcoma from an academic medical hospital in China. Int J Gynecol Cancer 2010; 20: 1535-1539
    Google Scholar
  • 25 Ashraf-Ganjoei T, Behtash N, Shariat M et al. Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol 2006; 4: 50
    CrossrefGoogle Scholar
  • 26 Ali RH, Rouzbahman M. Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. J Clin Pathol 2015; DOI: 10.1136/jclinpath-2014-202829.
    Google Scholar
  • 27 Leath 3rd CA, Huh WK, Hyde jr. J. et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 2007; 105: 630-634
    CrossrefGoogle Scholar
  • 28 Bai H, Yang J, Cao D et al. Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. Gynecol Oncol 2014; 132: 654-660
    CrossrefPubMedGoogle Scholar
  • 29 Chan JK, Kawar NM, Shin JY et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008; 99: 1210-1215
    CrossrefGoogle Scholar
  • 30 Pink D, Lindner T, Mrozek A et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2006; 101: 464-469
    CrossrefGoogle Scholar
  • 31 Cheng X, Yang G, Schmeler KM et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 2011; 121: 323-327
    CrossrefGoogle Scholar
  • 32 Beck TL, Singhal PK, Ehrenberg HM et al. Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment. Gynecol Oncol 2012; 125: 141-144
    CrossrefGoogle Scholar